Intellectual Property Magazine
USMCA’s biologics extension provision removed
Ben Wodecki
The controversial provision that granted pharma companies biologicpatent extensions has reportedly been removed from a newly
redesigned version
of the US-Mexico-Canada-Agreement (USMCA).